Claims for Patent: 5,846,547

Summary for Patent: 5,846,547

Title:	Streptococcal C5a peptidase vaccine
Abstract:	Novel vaccines for use against .beta.-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of streptococcal C5a peptidase, or a fragment or mutant thereof. Also disclosed is a method of protecting a susceptible mammal against .beta.-hemolytic Streptococcus colonization or infection by administering such a vaccine.
Inventor(s):	Cleary; Paul Patrick (Shoreview, MN)
Assignee:	Regents of the University of Minnesota (Minneapolis, MN)
Application Number:	08/589,756
Patent Claims:	1. A vaccine comrising an immunogenic amount of an enzymatically inactive streptococcal C5a peptidase (SCP), which amount is effective to reduce the incidence of or protect against .beta.-hemolytic Streptococcus colonization or infection in a susceptible mammal in combination with a physiologically-acceptable, non toxic vehicle. 2. The vaccine of claim 1 which further comprises an effective amount of an immunological adjuvant. 3. The vaccine of claim 1 wherein said mammal is selected from the group consisting of human, dog, bovine, porcine and horse. 4. The vaccine of claim 3 wherein said mammal is human. 5. The vaccine of claim 1 wherein said .beta.-hemolytic Streptococcus is selected from the group consisting of group A Streptococcus, group B Streptococcus, group C Streptococcus and group G Streptococcus. 6. A method according to claim 5, wherein said .beta.-hemolytic Streptococcus is Group A Streptococcus. 7. The vaccine of claim 1, which comprises a recombinant streptococcal C5a peptidase, conjugated or linked to a protein selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), ovalbumin, human serum albumin, human gamma globulin, chicken immunoglobulin G and bovine gamma globulin. 8. The vaccine of claim 1, which comprises said streptococcal C5a peptidase, conjugated or linked to a polysaccharide selected from the group consisting of group A Streptococci polysaccharide, capsular polysaccharides from group B Streptococci and capsular polysaccharides of Streptococci pnuemoniae. 9. A method of protecting a susceptible mammal against .beta.-hemolytic Streptoccocus colonization or infection comprising administering to said mammal an effective amount of a vaccine comprising an immunogenic amount of an enzymatically inactive streptococcal C5a peptidase (SCP), which amount is effective to reduce the incidence of or protect against Streptococcus colonization or infection in said susceptible mammal in combination with a physiologically-acceptable, non toxic vehicle. 10. The method of claim 9 wherein said vaccine further comprises an effective amount of an immunological adjuvant. 11. The method of claim 9 wherein said vaccine is administered by subcutaneous or intramuscular injection. 12. The method of claim 9 wherein said vaccine is administered by oral ingestion. 13. The method of claim 9 wherein said vaccine is administered intranasally. 14. A method according to claim 9, wherein said p-hemolytic Streptococcus is selected from the group consisting of group A Streptococcus, group B Streptococcus, group C Streptococcus and group G Streptococcus. 15. A method according to claim 14, wherein said .beta.-hemolytic Streptococcus is group A Streptococcus. 16. The method according to claim 9 wherein said mammal is selected from the group consisting of a human, dog, bovine, porcine, and horse. 17. The method according to claim 16 wherein said mammal is human. 18. The method of claim 9, wherein said vaccine comprises a recombinant streptococcal C5a peptidase, conjugated or linked to a protein selected from the group consisting of keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), ovalbumin, human serum albumin, human gamma globulin, chicken immunoglobulin G and bovine gamma globulin. 19. The method of claim 9, wherein said vaccine comprises a recombinant C5a peptidase, conjugated or linked to a polysaccharide selected from the group consisting of group A Streptococci polysaccharide, capsular polysaccharides from group B Streptococci and capsular polysaccharides of Streptococci pnuemoniae.

Details for Patent 5,846,547

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2040-01-28
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2040-01-28
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2040-01-28
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2040-01-28
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2040-01-28
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2040-01-28
Csl Behring Llc	ALBUMINAR, ALBUMINAR-20, ALBUMINAR-25, ALBUMINAR-5	albumin (human)	Injection	103955	03/17/2000		2040-01-28